skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Advances in the treatment of Raynaud’s phenomenon

Review

(3352) Views  (1847) Full article downloads

Authors: Terri L Levien

Published Date March 2010 Volume 2010:6 Pages 167 - 177
DOI: http://dx.doi.org/10.2147/VHRM.S4551

Terri L Levien

Drug Information Pharmacist and Clinical Associate Professor, College of Pharmacy, Washington State University Spokane, WA, USA

Abstract: Raynaud’s phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness. It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management is necessary. Calcium channel blockers are often used first-line, but in some patients are ineffective. Patients with severe symptoms or intolerance to available therapies have prompted exploration of alternative therapies, including endothelin antagonists, phosphodiesterase-5 inhibitors, antioxidants, newer vasodilators, statins, and botulinum toxin. These newer therapies provide the focus for this review.

Keywords: Raynaud, iloprost, bosentan, phosphodiesterase-5 inhibitors








Readers of this article also read:

Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Recent achievements in the management of Raynaud’s phenomenon
Mortality following operations for lower extremity peripheral arterial disease
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Impact of a diabetic foot care education program on lower limb amputation rate
Lower extremity arterial injuries over a six-year period: outcomes, risk factors, and management
Stent-grafts in the management of life-threatening hemorrhage following inadvertent femoral catheterization in high-risk patients: report of two cases and review of the literature
Lower extremity venous thrombosis in patients younger than 50 years of age
Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University